Kinase Inhibitors: Global Markets

NEW YORK, Aug. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Kinase Inhibitors: Global Markets

http://www.reportlinker.com/p0166819/Kinase-Inhibitors-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

INTRODUCTION

STUDY OBJECTIVES

This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.

A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.

R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in kinase inhibitor manufacture and use. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies active in the kinase inhibitor industry were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are: Reagents for Chromatography; Spectroscopy ? An Enduring Market; Advanced Drug Delivery Systems ? Technologies and Global Markets; Orthopedic Drugs, Implants and Devices ? Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry ? The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging ? Global Markets; Chiral Technology ? Global Markets; Autacoids and Related Drugs ? Technologies and Global Markets; Contraceptives ? Technologies and Global Markets; Liver Disease Treatments ? The Global Market; Hormone Replacement Therapies and Other Hormone Therapies ? Global Markets; Cardiovascular Medicine ? Diagnostics, Drugs and Devices; and Cancer Therapies ? Technologies and Global Markets.

TABLE OF CONTENTS

STUDY OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 1

SCOPE OF THE STUDY 2

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 2

RELATED BCC RESEARCH REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 SUMMARY 5

SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

SUMMARY FIGURE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016 ($

MILLIONS) 6

CHAPTER 3 OVERVIEW 8

DEFINITIONS 8

ENZYME INHIBITORS 8

WHY ENZYME INHIBITION? 8

USE OF ENZYME INHIBITORS 9

Mechanism of Enzyme Inhibition 9

Types of Enzyme Inhibitors 9

CLASSIFICATION OF ENZYME INHIBITORS 10

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10

KINASE INHIBITORS 11

HISTORY OF PROTEIN KINASES 12

TABLE 2 HISTORY OF PROTEIN KINASES 12

TYPES OF KINASE INHIBITORS 13

TABLE 3 TYPES OF KINASE INHIBITORS 13

Small Molecule Inhibitors 13

TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14

Antibody (Monoclonal) Inhibitors 14

CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION 14

SERINE/THREONINE KINASE INHIBITORS 14

TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15

TYROSINE KINASE INHIBITORS 15

Receptor Tyrosine Kinase (RTK) Inhibitors 16

TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16

Non-Receptor Tyrosine Kinase (NRTK) Inhibitors 16

TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16

CLASSIFICATION BY SITE OF ACTION 17

TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17

CHAPTER 4 REGULATORY ASPECTS 20

TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20

TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21

TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY

2012 22

TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23

MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS 24

TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE

INHIBITORS 24

TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE

KINASE INHIBITORS 24

TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE

KINASE INHIBITORS 24

TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE

KINASE INHIBITORS 25

TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25

CHAPTER 5 NEW DEVELOPMENTS 27

(RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 27

TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27

TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)

TKIS 28

TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)

TKIS 28

TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR

(VEGFR) TKIS 28

(NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 29

TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29

TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29

TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29

MULTIKINASE INHIBITORS 30

TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30

SERINE/THREONINE KINASE INHIBITOR 31

TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31

TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31

TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31

OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT 31

CHAPTER 6 GLOBAL MARKETS 34

MARKET ANALYSIS 34

TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35

FIGURE 1 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 35

TYROSINE KINASE INHIBITORS 36

TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($

MILLIONS) 36

FIGURE 2 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016 ($ MILLIONS) 36

Receptor Tyrosine Kinase Inhibitors 37

EGFR 38

PDGFR 38

VEGFR 38

HER2 39

Market Overview 39

Market Revenue 40

TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016

($ MILLIONS) 40

FIGURE 3 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 40

Non-Receptor Tyrosine Kinase Inhibitors 41

BCR-ABL 41

Janus Kinase (JAK) Inhibitor 42

Mesenchymal Epithelial Transition Growth Factor (c-MET) 42

Spleen Tyrosine Kinase (SYK) Inhibitors 42

Market Overview 43

Market Revenue 43

TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH

2016 ($ MILLIONS) 43

FIGURE 4 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016

($ MILLIONS) 43

Multikinase Inhibitors 44

Market Overview 44

Market Revenue 45

TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($

MILLIONS) 45

FIGURE 5 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($

MILLIONS) 45

SERINE/THREONINE KINASE INHIBITORS 46

mTOR Kinase Inhibitors 46

B RAF 46

RHO Kinase Inhibitors 47

Cyclin Dependant Kinase Inhibitor 47

Aurora Kinase Inhibitors 47

MAP/MEK Kinase Inhibitors 47

JNK Inhibitors 48

Protein Kinase C Inhibitors 48

PI3K Inhibitors 48

Market Overview 49

Market Revenue 49

TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($

MILLIONS) 49

FIGURE 6 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 50

MONOCLONAL ANTIBODY KINASE INHIBITOR 50

Humanized Monoclonal Antibody 51

Chimeric Monoclonal Antibody 51

Human Monoclonal Antibody 52

Market Overview 52

Market Revenue 53

TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH

2016 ($ MILLIONS) 53

FIGURE 7 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016

($ MILLIONS) 53

MARKET SHARE 54

RECEPTOR TYROSINE KINASE INHIBITORS 54

TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54

FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54

NON-RECEPTOR TYROSINE KINASE INHIBITORS 55

MULTI-TARGET KINASE INHIBITORS 55

TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55

FIGURE 9 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55

SERINE/THREONINE KINASE INHIBITORS 56

TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 56

FIGURE 10 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 56

MONOCLONAL ANTIBODY KINASE INHIBITORS 57

TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010

(%) 57

FIGURE 11 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION,

2010 (%) 57

MARKET BY APPLICATIONS 58

MARKET REVENUE 59

TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($

MILLIONS) 60

FIGURE 12 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($

MILLIONS) 60

ANTINEOPLASTIC AGENTS 60

TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 64

FIGURE 13 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 64

IMMUNOSUPPRESSANTS 64

TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

THROUGH 2016 ($ MILLIONS) 65

FIGURE 14 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 65

AGE-RELATED MACULAR DEGENERATION 66

TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 67

FIGURE 15 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 67

MARKET SHARE 68

TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 68

FIGURE 16 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 68

CHAPTER 7 MARKETS IN THE UNITED STATES 70

MARKET ANALYSIS 70

TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 70

FIGURE 17 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 70

TYROSINE KINASE INHIBITORS 71

TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71

FIGURE 18 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 72

Receptor Tyrosine Kinase Inhibitors 72

EGFR 73

PDGFR 73

VEGFR 73

HER2 74

Market Overview 74

Market Revenue 75

TABLE 47 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 75

FIGURE 19 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 75

Non-Receptor Tyrosine Kinase Inhibitors 76

BCR-ABL 76

Janus Kinase (JAK) Inhibitor 77

Mesenchymal Epithelial Transition Growth Factor (c-MET) 77

Spleen Tyrosine Kinase (SYK) Inhibitors 77

Market Overview 78

Market Revenue 78

TABLE 48 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH

2016 ($ MILLIONS) 78

FIGURE 20 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 78

Multikinase Inhibitors 79

Market Overview 79

Market Revenue 80

TABLE 49 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016 ($

MILLIONS) 81

FIGURE 21 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($ MILLIONS) 81

SERINE/THREONINE KINASE INHIBITORS 81

M TOR Kinase Inhibitors 81

B RAF 82

RHO Kinase Inhibitors 82

Cyclin Dependant Kinase Inhibitor 82

Aurora Kinase Inhibitors 82

MAP/MEK Kinase Inhibitors 83

JNK Inhibitors 83

Protein Kinase C Inhibitors 83

PI3K Inhibitors 84

Market Overview 84

Market Revenue 85

TABLE 50 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 85

FIGURE 22 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 86

MONOCLONAL ANTIBODY KINASE INHIBITOR 86

Humanized Monoclonal Antibody 87

Chimeric Monoclonal Antibody 87

Human Monoclonal Antibody 88

Market Overview 88

Market Revenue 89

TABLE 51 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016

($ MILLIONS) 89

FIGURE 23 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016 ($

MILLIONS) 89

MARKET SHARE OF INDUSTRY LEADERS IN U.S 90

RECEPTOR TYROSINE KINASE INHIBITORS 90

TABLE 52 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 90

FIGURE 24 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 90

NON-RECEPTOR TYROSINE KINASE INHIBITORS 90

MULTI-TARGET KINASE INHIBITORS 91

TABLE 53 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 91

FIGURE 25 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 91

SERINE/ THREONINE KINASE INHIBITORS 91

TABLE 54 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 91

FIGURE 26 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 92

ANTIBODY KINASE INHIBITORS 92

TABLE 55 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010

(%) 93

FIGURE 27 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010

(%) 93

MARKET APPLICATIONS 93

MARKET REVENUE 94

TABLE 56 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016 ($

MILLIONS) 94

FIGURE 28 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($

MILLIONS) 95

ANTINEOPLASTIC AGENTS 95

TABLE 57 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 99

FIGURE 29 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 99

IMMUNOSUPPRESSANTS 100

TABLE 58 U.S. MARKET FOR KINASE INHIBITORS USED AS

IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 100

FIGURE 30 U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 100

AGE-RELATED MACULAR DEGENERATION 101

TABLE 59 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 102

FIGURE 31 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 102

MARKET SHARE 103

TABLE 60 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103

FIGURE 32 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103

CHAPTER 8 MARKETS IN EUROPE 105

MARKET ANALYSIS 105

TABLE 61 EUROPEAN MARKET FOR KINASE INHIBITORS THROUGH 2016 ($ MILLIONS) 105

FIGURE 33 EUROPEAN MARKET FOR KINASE INHIBITORS, 2009- 2016 ($ MILLIONS) 105

TYROSINE KINASE INHIBITORS 106

TABLE 62 EUROPEAN MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 106

FIGURE 34 EUROPEAN MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 106

Receptor Tyrosine Kinase Inhibitors 107

EGFR 107

PDGFR 107

VEGFR 108

HER2 108

Market Overview 109

Market Revenue 109

TABLE 63 EUROPEAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH

2016 ($ MILLIONS) 109

FIGURE 35 EUROPEAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016

($ MILLIONS) 110

Non-Receptor Tyrosine Kinase Inhibitors 110

BCR-ABL 111

Janus Kinase (JAK) Inhibitor 111

Mesenchymal Epithelial Transition Growth Factor (c-MET) 111

Spleen Tyrosine Kinase (SYK) Inhibitors 112

Market Overview 112

Market Revenue 113

TABLE 64 EUROPEAN MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR,

THROUGH 2016 ($ MILLIONS) 113

Multikinase Inhibitors 113

Market Overview 113

Market Revenue 114

TABLE 65 EUROPEAN MARKET FOR MULTIKINASE TYROSINE KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 114

FIGURE 36 EUROPEAN MARKET FOR MULTIKINASE TYROSINE KINASE INHIBITORS,

2009-2016 ($ MILLIONS) 115

SERINE/THREONINE KINASE INHIBITORS 115

M TOR Kinase Inhibitors 115

B-RAF Kinase Inhibitors 115

RHO Kinase Inhibitors 116

Cyclin-Dependant Kinase Inhibitor 116

Aurora Kinase Inhibitors 116

MAP/MEK Kinase Inhibitors 117

JNK Inhibitors 117

Protein Kinase C Inhibitors 117

PI3K Inhibitors 118

Market Overview 118

Market Revenue 119

TABLE 66 EUROPEAN MARKET FOR SERINE/THREONINE KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 119

FIGURE 37 EUROPE MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 119

MONOCLONAL ANTIBODIES 120

Humanized Monoclonal Antibody 121

Chimeric Monoclonal Antibody 121

Human Monoclonal Antibody 121

Market Overview 121

Market Revenue 123

TABLE 67 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 123

FIGURE 38 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,

2009-2016 ($ MILLIONS) 123

MARKET SHARES OF INDUSTRY LEADERS IN EUROPE 124

RECEPTOR TYROSINE KINASE INHIBITORS 124

TABLE 68 EUROPEAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 125

FIGURE 39 EUROPEAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 125

NON-RECEPTOR TYROSINE KINASE INHIBITORS 125

MULTI-TARGET KINASE INHIBITORS 125

TABLE 69 EUROPEAN MARKET SHARE OF MULTI-TARGET KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 126

FIGURE 40 EUROPEAN MARKET SHARE OF MULTI-TARGET KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 126

SERINE/ THREONINE KINASE INHIBITORS 126

TABLE 70 EUROPEAN MARKET SHARE OF SERINE/THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 127

FIGURE 41 EUROPEAN MARKET SHARE OF SERINE/THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 127

ANTIBODY KINASE INHIBITORS 127

TABLE 71 EUROPEAN MARKET SHARES OF ANTIBODY KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 127

FIGURE 42 EUROPEAN MARKET SHARE OF ANTIBODY KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 127

MARKET APPLICATIONS 128

MARKET REVENUE 129

TABLE 72 EUROPEAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016

($ MILLIONS) 130

FIGURE 43 EUROPEAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($

MILLIONS) 130

ANTINEOPLASTIC AGENTS 130

TABLE 73 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC

AGENTS, THROUGH 2016 ($ MILLIONS) 134

FIGURE 44 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC

AGENTS, 2009-2016 ($ MILLIONS) 134

IMMUNOSUPPRESSANTS 135

TABLE 74 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

THROUGH 2016 ($ MILLIONS) 136

FIGURE 45 EUROPEAN MARKET FOR KINASE INHIBITORS USED AS

IMMUNOSUPPRESSANTS, 2009-2016 ($ MILLIONS) 136

AGE-RELATED MACULAR DEGENERATION 136

TABLE 75 EUROPEAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 137

FIGURE 46 EUROPEAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED

MACULAR DEGENERATION, 2009-2016 ($ MILLIONS) 137

Market Share 138

TABLE 76 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, IN EUROPE, 2010 (%) 138

FIGURE 47 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, IN EUROPE, 2010

(%) 138

CHAPTER 9 MARKETS IN ASIA 140

MARKET ANALYSIS 140

TABLE 77 ASIAN MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 141

FIGURE 48 ASIAN MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 141

TYROSINE KINASE INHIBITORS 142

TABLE 78 ASIAN MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 142

FIGURE 49 ASIAN MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 142

Receptor Tyrosine Kinase Inhibitors 143

EGFR 143

PDGFR 143

VEGFR 144

HER2 144

Market Overview 144

Market Revenue 145

TABLE 79 ASIAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 145

FIGURE 50 ASIAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS 2009-2016 ($

MILLIONS) 145

Non-Receptor Tyrosine Kinase Inhibitors 146

BCR-ABL 146

Janus Kinase (JAK) Inhibitor 147

Mesenchymal Epithelial Transition Growth Factor (c-MET) 147

Spleen Tyrosine Kinase (SYK) Inhibitors 147

Market Overview 148

Market Revenue 148

TABLE 80 ASIAN MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 148

Multikinase Inhibitors 148

Market Overview 148

Market Revenue 149

TABLE 81 ASIAN MARKET FOR MULTIKINASE TYROSINE KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 149

FIGURE 51 ASIAN MARKET FOR MULTIKINASE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 149

SERINE/THREONINE KINASE INHIBITORS 150

M TOR Kinase Inhibitors 150

B RAF Kinase Inhibitors 151

RHO Kinase Inhibitors 151

Cyclin-Dependant Kinase Inhibitor 151

Aurora Kinase Inhibitors 151

MAP/MEK Kinase Inhibitors 152

JNK Inhibitors 152

Protein Kinase C Inhibitors 152

PI3K Inhibitors 153

Market Overview 153

Market Revenue 153

TABLE 82 ASIAN MARKET FOR SERINE/THREONINE KINASE INHIBITORS THROUGH 2016 ($

MILLIONS) 153

FIGURE 52 ASIAN MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 154

MONOCLONAL ANTIBODIES 154

Humanized Monoclonal Antibody 155

Chimeric Monoclonal Antibody 155

Human Monoclonal Antibody 155

Market Overview 156

Market Revenue 157

TABLE 83 ASIAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 157

FIGURE 53 ASIAN MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITORS, 2009-2016

($ MILLIONS) 157

MARKET SHARE OF INDUSTRY LEADERS IN ASIA 158

RECEPTOR TYROSINE KINASE INHIBITORS 158

TABLE 84 ASIAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 158

FIGURE 54 ASIAN MARKET SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 158

NON-RECEPTOR TYROSINE KINASE INHIBITORS 158

MULTI-TARGET KINASE INHIBITORS 159

TABLE 85 ASIAN MARKET SHARE OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 159

FIGURE 55 ASIAN MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 159

SERINE/THREONINE KINASE INHIBITORS 159

TABLE 86 ASIAN MARKET SHARE OF SERINE/THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 160

FIGURE 56 ASIAN MARKET SHARES OF SERINE/THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 160

ANTIBODY KINASE INHIBITORS 160

TABLE 87 ASIAN MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS,

2010 (%) 161

FIGURE 57 ASIAN MARKET SHARES OF ANTIBODY KINASE INHIBITOR MANUFACTURERS,

2010 (%) 161

MARKET APPLICATIONS 161

MARKET REVENUE 163

TABLE 88 ASIAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS THROUGH 2016 ($

MILLIONS) 163

FIGURE 58 ASIAN MARKET FOR KINASE INHIBITORS BY APPLICATIONS 2009-2016 ($

MILLIONS) 163

ANTINEOPLASTIC AGENTS 163

TABLE 89 ASIAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 166

FIGURE 59 ASIAN MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 167

IMMUNOSUPPRESSANTS 167

TABLE 90 ASIAN MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

THROUGH 2016 ($ MILLIONS) 168

FIGURE 60 ASIAN MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 168

AGE-RELATED MACULAR DEGENERATION 169

TABLE 91 ASIAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 170

FIGURE 61 ASIAN MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 170

Market Share 171

TABLE 92 MARKET SHARE OF KINASE INHIBITORS IN ASIA, BY APPLICATION, 2010 (%) 171

FIGURE 62 MARKET SHARE OF KINASE INHIBITORS IN ASIA, BY APPLICATION, 2010 (%) 171

CHAPTER 10 EMERGING MARKETS 173

MARKET ANALYSIS 173

TABLE 93 EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 173

FIGURE 63 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 174

TYROSINE KINASE INHIBITORS 174

TABLE 94 EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 174

FIGURE 64 EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 175

Receptor Tyrosine Kinase Inhibitors 175

EGFR 176

PDGFR 176

VEGFR 176

HER2 (Human Epidermal Growth Factor Receptor 2) 177

Market Overview 177

Market Revenue 177

TABLE 95 EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 178

FIGURE 65 EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS,

2009-2016 ($ MILLIONS) 178

Non-Receptor Tyrosine Kinase Inhibitors 179

BCR-ABL 179

Janus Kinase (JAK) Inhibitor 179

Mesenchymal Epithelial Transition Growth Factor (c-MET) 179

Spleen Tyrosine Kinase (SYK) Inhibitors 180

Market Overview 180

Market Revenue 181

TABLE 96 EMERGING MARKETS FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 181

Multikinase Inhibitors 181

Market Overview 181

Market Revenue 181

TABLE 97 EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 182

FIGURE 66 EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS,

2009-2016 ($ MILLIONS) 182

SERINE/THREONINE KINASE INHIBITORS 182

mTOR Kinase Inhibitors 182

B RAF Kinase Inhibitors 183

RHO Kinase Inhibitors 183

Cyclin-Dependant Kinase Inhibitor 183

Aurora Kinase Inhibitors 183

MAP/MEK Kinase Inhibitors 184

JNK Inhibitors 184

Protein Kinase C Inhibitors 184

PI3K Inhibitors 185

Market Overview 185

Market Revenue 186

TABLE 98 EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 186

FIGURE 67 EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016

($ MILLIONS) 186

MONOCLONAL ANTIBODIES 187

Humanized Monoclonal Antibody 188

Chimeric Monoclonal Antibody 188

Human Monoclonal Antibody 188

Market Overview 189

Market Revenue 189

TABLE 99 EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 190

FIGURE 68 EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,

2009-2016 ($ MILLIONS) 190

MARKET SHARE OF INDUSTRY LEADERS IN EMERGING MARKETS 190

RECEPTOR TYROSINE KINASE INHIBITORS 190

TABLE 100 SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN

EMERGING MARKETS, 2010 (%) 191

FIGURE 69 SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN

EMERGING MARKETS, 2010 (%) 191

NON-RECEPTOR TYROSINE KINASE INHIBITORS 191

MULTI-TARGET KINASE INHIBITORS 191

TABLE 101 SHARE OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN EMERGING

MARKETS, 2010 (%) 192

FIGURE 70 SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN

EMERGING MARKETS, 2010 (%) 192

SERINE/THREONINE KINASE INHIBITORS 192

TABLE 102 SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN

EMERGING MARKETS, 2010 (%) 192

FIGURE 71 SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN

EMERGING MARKETS, 2010 (%) 192

ANTIBODY KINASE INHIBITORS 193

TABLE 103 SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS IN EMERGING

MARKETS 2010 (%) 193

FIGURE 72 SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS IN EMERGING

MARKETS, 2010 (%) 193

MARKET APPLICATIONS 194

MARKET REVENUE 195

TABLE 104 EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, THROUGH

2016 ($ MILLIONS) 195

FIGURE 73 EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($

MILLIONS) 195

ANTINEOPLASTIC AGENTS 196

TABLE 105 EMERGING MARKETS FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC

AGENTS, THROUGH 2016 ($ MILLIONS) 198

FIGURE 74 EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($

MILLIONS) 198

IMMUNOSUPPRESSANTS 199

TABLE 106 EMERGING MARKETS FOR KINASE INHIBITORS USED AS

IMMUNOSUPPRESSANTS, THROUGH 2016 ($ MILLIONS) 200

FIGURE 75 EMERGING MARKETS FOR KINASE INHIBITORS USED AS

IMMUNOSUPPRESSANTS, 2009-2016 ($ MILLIONS) 200

AGE-RELATED MACULAR DEGENERATION 201

TABLE 107 EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED

MACULAR DEGENERATION, THROUGH 2016 ($ MILLIONS) 202

FIGURE 76 EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED

MACULAR DEGENERATION, 2009-2016 ($ MILLIONS) 202

MARKET SHARE 202

TABLE 108 SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION, 2010

(%) 203

FIGURE 77 SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION, 2010

(%) 203

CHAPTER 11 PATENT ANALYSIS 205

PATENTS BY YEAR 205

TABLE 109 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 205

FIGURE 78 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 205

FIGURE 79 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 (%) 206

PATENTS BY CATEGORY 206

TABLE 110 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 207

FIGURE 80 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 207

PATENTS BY TYPE 207

TABLE 111 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF

FEBRUARY 2012 207

FIGURE 81 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF

FEBRUARY 2012 208

TABLE 112 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 208

FIGURE 82 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 208

PATENTS BY COMPANY 209

TABLE 113 NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO

END OF FEBRUARY 2012 209

PATENTS BY COUNTRY 210

TABLE 114 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 210

FIGURE 83 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO

END OF FEBRUARY 2012 210

TABLE 115 PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 211

FIGURE 84 PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010-2012 (%) 211

PATENTS BY ASSIGNEE 212

TABLE 116 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF

FEBRUARY 2012 212

FIGURE 85 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF

FEBRUARY 2012 212

CHAPTER 12 CURRENT STATUS 215

CANCER AND KINASE INHIBITORS 215

MULTIPLE SINGLE KINASE INHIBITORS VERSUS SINGLE MULTIKINASE INHIBITORS 216

EFFICACY 216

RESISTANCE 216

PHARMACOKINETICS 217

Selectivity 217

TUMOR MICROENVIRONMENT 217

TOXICITY 218

FUTURE DIRECTIONS 218

CHAPTER 13 COMPANY PROFILES 220

ABBOTT LABORATORIES 220

AMGEN INC. 220

ARQULE, INC. 221

ARRAY BIOPHARMA 221

ASTRAZENECA 222

AVEO PHARMACEUTICALS, INC. 222

BAYER AG 222

BRISTOL-MYERS SQUIBB 223

BOEHRINGER INGELHEIM 223

CYTRX CORPORATION 223

EISAI INC 224

ETON BIOSCIENCE, INC. 224

EXELIXIS, INC. 225

GLAXOSMITHKLINE 225

MERCK SERONO SA 226

NOVARTIS INTERNATIONAL AG 226

OSI PHARMACEUTICALS LLC 227

PFIZER 227

ROCHE GROUP 228

S*BIO PTE LTD 228

SANOFI-AVENTIS 228

TAKEDA PHARMACEUTICALS 229

CHAPTER 14 ABBREVIATIONS 231

LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($MILLIONS) 6TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10TABLE 2 HISTORY OF PROTEIN KINASES 12TABLE 3 TYPES OF KINASE INHIBITORS 13TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY2012 22TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASEINHIBITORS 24TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINEKINASE INHIBITORS 24TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINEKINASE INHIBITORS 24TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASEINHIBITORS 25TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)TKIS 28TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)TKIS 28TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR(VEGFR) TKIS 28TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($MILLIONS) 36TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016 ($MILLIONS) 40TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH2016 ($ MILLIONS) 43TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($MILLIONS) 45TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($MILLIONS) 49TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH2016 ($ MILLIONS) 53TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 56TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010(%) 57TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($MILLIONS) 60TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,THROUGH 2016 ($ MILLIONS) 64TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 65TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULARDEGENERATION, THROUGH 2016 ($ MILLIONS) 67TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 68TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 70TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71TABLE 47 U.S. MARKET FOR RECEPTOR TYROS

To order this report:Therapy Industry: Kinase Inhibitors: Global Markets

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker